Robert T. Foster's most recent trade in Aurinia Pharmaceuticals Inc was a trade of 32,900 Stock Option (right to buy) done . Disclosure was reported to the exchange on Sept. 21, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc | T. Foster Robert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2023 | 32,900 | 32,900 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Robert T. Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2023 | 20,383 | 20,383 | - | - | Restricted Stock Units | |
| Hepion Pharmaceuticals Inc | Robert T. Foster | Director, CEO, CSO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 1,900,000 | 2,501,879 | - | - | Stock Options | |
| Hepion Pharmaceuticals Inc | Robert T. Foster | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 2.00 per share. | 18 Feb 2021 | 20,000 | 45,259 (1%) | 0% | 2 | 40,000 | Common Stock |
| Hepion Pharmaceuticals Inc | Robert T. Foster | Director, CEO and Director | Purchase of securities on an exchange or from another person at price $ 1.58 per share. | 08 Dec 2020 | 25,000 | 25,259 (0%) | 0% | 1.6 | 39,418 | Common Stock |
| Hepion Pharmaceuticals Inc | Robert T. Foster | Director, CEO,CSO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2020 | 212,000 | 601,879 | - | - | Stock Options |